Held by VIR, the Realising Resolution 29: New Approaches for Pharma-Healthcare Development event will focus discussions on the importance of Resolution No.29-NQ/TW to the future sustainable development of Vietnam’s health system, learning lessons from other nations, identifying where there is room for improvement, and promoting public-private collaborations.
|VIR to host health conference on July 20 |
The conference will feature keynote speeches from Emin Turan, chairman of Pharma Group, and Eunice Cho, country manager of Viatris Vietnam Ltd., as well as two panel discussions.
Vietnam’s pharma and healthcare sector has witnessed significant contributions from all stakeholders over the years, including foreign-invested enterprises, but alongside the many achievements, significant obstacles lay ahead. Overcoming them requires innovation and strengthened cooperation from all involved to ensure its sustainable development.
Investment trends in pharma and healthcare have shifted towards focusing on innovative machinery, technology transfer, and more to further contribute to the country’s common goal of better protecting and improving people's health.
Recent moves by multinational corporations have reinforced the trend. In particular, the presence of Viatris in Vietnam is a strategic move for the company to achieve its mission of empowering people worldwide to live more healthily at every stage of their lives.
Cho said, “In addition to seeing good growth potential for the company, we understand that our performance in Vietnam is in line with our purpose of meeting the nation's health needs and ensuring access to quality medicines. We work to promote responsible and sustainable operations, and I am extremely confident of the value our company will bring to our patients, employees, customers, and society as a whole.”
The recent collaboration with Medochemie is intended to further fuel the company’s efforts to support the Vietnamese government’s goal of enabling technology transfer to strengthen domestic manufacturing capabilities. The ultimate vision is to make Vietnam the ASEAN hub for pharmaceutical manufacturing over the next 10-20 years.
“Our relentless pursuit is to improve access to high-quality, trusted medicines. This cooperation is yet another milestone in our localisation efforts and our commitment to expanding the access to quality medicines to the people of Vietnam,” she noted.
“We will continue to work and support the government’s vision to foster access to quality medicine through local manufacturing,” Cho concluded.
Within the latest development period, Resolution 29 on the acceleration of the national industrialisation and modernisation to 2030 with a vision to 2045 has become a guide for sectors like healthcare.
Turan said that realising the goals in Resolution 29 means generating breakthroughs in the pharma sector's development, which require the adoption of innovative approaches and clearly defined policy priorities to achieve the long-term goals. This will not only foster the sector’s growth and innovation, but also create spillover effects and driving forces for other industries.
“Pharma Group Vietnam represents the voice of innovation in the pharmaceutical industry, and wholeheartedly supports the orientation set forth in Resolution 29 to establish pharmaceuticals as one of the priority sectors that will enable and drive innovation. We are optimistic that the upcoming Government Action Plan to implement the resolution will enable breakthrough solutions and yield significant outcomes,” he noted.
The event is expected to set off a platform for policymakers and the business community to discuss the issue, as well as help foster business cooperation opportunities.
The half-day conference, set to take place from 8.30am to 12pm on July 20 at the Pullman Hotel in Hanoi, will be covered extensively across VIR’s various print and online offerings, on leading TV channels, and through other media agencies.
Panellists at the first discussion:
- Phan Duc Hieu, Standing Member of the Economic Committee of the National Assembly
- Do Van Su, Deputy Director of the Foreign Investment Agency under The Ministry of Planning and Investment
- Ta Manh Hung, Deputy Director of the Drug Administration of Vietnam under the Ministry of Health
- Emin Turan, Chairman of Pharma Group
- Prof. Nguyen Hai Nam, Rector of Hanoi University of Pharmacy
Panellists at the second discussion:
- Nguyen Hoa Cuong, Deputy Director of the Central Institute for Economic Development
- Prof. Dr. Nguyen Manh Cuong, Deputy Director, Institute of Natural Products Chemistry, Vietnam Academy of Science and Technology
- Trinh Van Lau, Chairman of Vietnam Pharmaceutical Companies Association
- Luke Treloar, Partner, Head of Strategy, and National Head of Healthcare and Life Sciences at KPMG Vietnam